These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 513956)

  • 41. Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity.
    Scatton B
    J Pharmacol Exp Ther; 1982 Jan; 220(1):197-202. PubMed ID: 6118430
    [No Abstract]   [Full Text] [Related]  

  • 42. Biphasic modulation of evoked [3H]D-aspartate release by D-2 dopamine receptors in rat striatal slices.
    Peris J; Dwoskin LP; Zahniser NR
    Synapse; 1988; 2(4):450-6. PubMed ID: 2973144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An analysis of the effects of apomorphine and haloperidol on the release of [3H]-dopamine and [3H]-noradrenaline from rabbit brain slices.
    Kelly MJ
    Arch Int Pharmacodyn Ther; 1981 Mar; 250(1):18-29. PubMed ID: 7271378
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modulation by dopaminergic and serotonergic systems of cholinergic interneurons in nucleus accumbens and striatum.
    Bluth R; Langnickel R; Ott T
    Pol J Pharmacol Pharm; 1985; 37(6):753-63. PubMed ID: 3832017
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interactions between endogenous dopamine and dopamine agonists at release modulatory receptors: multiple effects of neuronal uptake inhibitors on transmitter release.
    Hoffmann IS; Talmaciu RK; Cubeddu LX
    J Pharmacol Exp Ther; 1986 Aug; 238(2):437-46. PubMed ID: 2942676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antidopaminergic properties of yohimbine.
    Scatton B; Zivkovic B; Dedek J
    J Pharmacol Exp Ther; 1980 Nov; 215(2):494-9. PubMed ID: 7192314
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of haloperidol and low dose clozapine on the acetylcholine turnover rate in rat forebrain structures.
    Bluth R; Langnickel R
    Biomed Biochim Acta; 1985; 44(10):1531-9. PubMed ID: 4084256
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increase in striatal acetylcholine levels in vivo by piribedil a new dopamine receptor stimulant.
    Ladinsky H; Consolo S; Garattini S
    Life Sci; 1974 Apr; 14(7):1251-60. PubMed ID: 4823638
    [No Abstract]   [Full Text] [Related]  

  • 49. Neurotensin regulation of endogenous acetylcholine release from rat striatal slices is independent of dopaminergic tone.
    Lapchak PA; Araujo DM; Quirion R; Beaudet A
    J Neurochem; 1991 Feb; 56(2):651-7. PubMed ID: 1899109
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alterations in dopamine release from striatal slices of rats after chronic treatment with haloperidol.
    Yamada S; Yokoo H; Harajiri S; Nishi S
    Eur J Pharmacol; 1991 Jan; 192(1):141-5. PubMed ID: 2040357
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice.
    Kovács GL; Szabó G; Penke B; Telegdy G
    Eur J Pharmacol; 1981 Jan; 69(3):313-9. PubMed ID: 6260512
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of cyclo (Leu-Gly) on neurochemical indices of striatal dopaminergic supersensitivity induced by prolonged haloperidol treatment.
    Le Douarin C; Fage D; Scatton B
    Life Sci; 1984 Jan; 34(4):393-9. PubMed ID: 6694528
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopaminergic inhibition of striatal acetylcholine release after 6-hydroxydopamine.
    MacKenzie RG; Stachowiak MK; Zigmond MJ
    Eur J Pharmacol; 1989 Sep; 168(1):43-52. PubMed ID: 2511032
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Studies on the mechanism of depletion of striatal dopamine by alpha-methyl-m-tyrosine.
    Uretsky NJ; Snodgrass SR; Lorenzo AV
    J Pharmacol Exp Ther; 1975 Dec; 195(3):465-79. PubMed ID: 490
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functional antagonism of D-1 and D-2 dopaminergic mechanisms affecting striatal acetylcholine release.
    Gorell JM; Czarnecki B; Hubbell S
    Life Sci; 1986 Jun; 38(24):2247-54. PubMed ID: 2940433
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On the relation between haloperidol-induced alterations in DA release and DA metabolism in rat striatum.
    Moleman P; Bruinvels J; van Valkenburg CF
    Life Sci; 1978 Aug; 23(6):611-5. PubMed ID: 692284
    [No Abstract]   [Full Text] [Related]  

  • 57. Cortical and striatal in vivo uptake and metabolism of plasma choline in the rat: effects of haloperidol and apomorphine.
    Aquilonius SM; Eckernäs SA
    Acta Pharmacol Toxicol (Copenh); 1976 Jul; 39(1):129-40. PubMed ID: 988965
    [No Abstract]   [Full Text] [Related]  

  • 58. The effect of neuroleptics on acetylcholine concentration and choline uptake in striatum: Implications for regulation of acetylcholine metabolism.
    Sherman KA; Hanin I; Zigmond MJ
    J Pharmacol Exp Ther; 1978 Sep; 206(3):677-86. PubMed ID: 29960
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat.
    Rupniak NM; Hall MD; Mann S; Fleminger S; Kilpatrick G; Jenner P; Marsden CD
    Biochem Pharmacol; 1985 Aug; 34(15):2755-63. PubMed ID: 4040370
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation of dopamine receptors inhibits calcium-dependent glutamate release from cortico--striatal terminals in vitro.
    Rowlands GF; Roberts PJ
    Eur J Pharmacol; 1980 Mar; 62(2-3):241-2. PubMed ID: 7379845
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.